

BAXTER INTERNATIONAL INC.
Key Product Line Sales by US and International
Three-Month Periods Ending December 31, 2009 and 2008
(unaudited)
(\$ in millions)

	Q4 2009			Q4 2008			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants	\$242	\$322	\$564	\$219	\$287	\$506	11%	12%	11%
Plasma Proteins	136	244	380	132	198	330	3%	23%	15%
Antibody Therapy	237	114	351	228	81	309	4%	41%	14%
Regenerative Medicine	66	59	125	56	45	101	18%	31%	24%
Other ¹	13	85	98	12	101	113	8%	(16%)	(13%)
Total BioScience	\$694	\$824	\$1,518	\$647	\$712	\$1,359	7%	16%	12%
Medication Delivery									
IV Therapies	\$129	\$309	\$438	\$123	\$270	\$393	5%	14%	11%
Global Injectables	252	227	479	242	178	420	4%	28%	14%
Infusion Systems	144	102	246	134	88	222	7%	16%	11%
Anesthesia	90	50	140	88	43	131	2%	16%	7%
Other	0	9	9	3	5	8	(100%)	80%	13%
Total Medication Delivery	\$615	\$697	\$1,312	\$590	\$584	\$1,174	4%	19%	12%
Renal									
PD Therapy	\$79	\$430	\$509	\$76	\$382	\$458	4%	13%	11%
HD Therapy	21	95	116	22	77	99	(5%)	23%	17%
Total Renal	\$100	\$525	\$625	\$98	\$459	\$557	2%	14%	12%
Baxter excluding Transfusion Therapies	\$1,409	\$2,046	\$3,455	\$1,335	\$1,755	\$3,090	6%	17%	12%
Transfusion Therapies ²	\$10	\$5	\$15	\$17	\$24	\$41	(41%)	(79%)	(63%)
Total Baxter	\$1,419	\$2,051	\$3,470	\$1,352	\$1,779	\$3,131	5%	15%	11%

¹ Principally includes vaccines and sales of plasma to third parties.

² Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.